Clinical trials: Dermatitis
Atopic Dermatitis
A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
To assess the safety, tolerability and efficacy of CIM331, compared to placebo, in atopic dermatitis patients who are inadequately controlled by or intolerant to topical therapy
- Trial name
- NCT01986933
- Testing
- nemolizumab (CIM331)
- Where
- 18 sites in United States
- Volunteers
- 264 people
- Sponsor
- Chugai Pharmaceutical
Dermatitis, Atopic
A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis
The objective of this study is to evaluate the safety and tolerability of multiple intravenous (IV) infusions of KHK4083 in subjects with moderate or severe atopic dermatitis.
- Trial name
- NCT03096223
- Testing
- KHK4083
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Atopic Diathesis, Eczema-prone Skin
Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis
The aim of this study is to compare the efficacy and tolerability and of a cosmetic product to one that is already available on the market (benchmark product).
- Trial name
- NCT05807113
- Testing
- Atopi intensive care BNO 3731, Benchmark product
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bionorica SE
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome
Topical Infliximab in Autoimmune Eyes With Keratoprosthesis
The Boston Keratoprosthesis type I (KPro) is a prosthetic cornea used to treat several causes of corneal blindness. Some categories of patients, including those with auto-immune diseases such as Stevens-Johnson syndrome, toxic…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis (Lyell) Syndrome, Mucous Membrane Pemphigoid
- Trial name
- NCT02126020
- Testing
- topical infliximab
- Where
- 2 sites in United States, Canada
- Sponsor
- James Chodosh, MD, MPH
Atopic Dermatitis
Bioequivalence of Two Tacrolimus 0.1% Topical Ointment Formulations in Patients With Atopic Dermatitis
The primary objectives are to establish the therapeutic equivalence of tacrolimus ointment 0.1%, manufactured by Taro Pharmaceuticals Inc.
- Trial name
- NCT00833079
- Testing
- Tacrolimus 0.1% manufactured by Taro, Protopic - Tacrolimus 0.1%, Tacrolimus Vehicle manufactured by Taro
- Volunteers
- 500 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Xerosis, Xerosis Cutis
Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin
The purpose of the study is to compare the changes in the appearance of dry skin after the use various moisturizers: white petrolatum ointment, coconut oil, jojoba oil, and almond oil in patients with dry skin.
- Conditions
- Xerosis, Xerosis Cutis, Dry Skin; Eczema
- Trial name
- NCT03093597
- Testing
- virgin coconut oil, virgin jojoba oil, virgin almond oil
- Where
- 2 sites in United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Psoriasis, Inflammation
Role of CD7 in Skin Inflammation and Psoriasis
Role of CD7 in skin inflammation and psoriasis
- Trial name
- NCT00162825
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Atopic Dermatitis
Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)
The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.
- Trial name
- NCT06101823
- Testing
- OpSCF
- Where
- 22 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Insmed Incorporated
Head and Neck Carcinoma
Trial of OTD70DERM® in Radio-dermatitis Induced by Radiotherapy-Erbitux®
The aim of this randomized trial is to compare the rate of radio-dermatitis grade 2+ (NCI-CTC V3.0) in patients receiving radiotherapy+Erbitux+placebo versus in patients receiving radiotherapy+Erbitux+OTD70DERM® for the treatment…
- Trial name
- GORTEC 2009-01 (NCT01228565)
- Testing
- Radiotherapy+Erbitux+OTD70DERM
- Where
- 5 sites in France
- Volunteers
- 76 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
Eczema, Psoriasis
Non-invasive Photoacoustic Imaging of Skin Inflammatory Disorders With Machine Learning-assisted Scoring
Inflammatory skin disorders are usually assessed by disease scoring system such as Scoring AD (SCORAD)/Eczema Area and Severity Index (EASI) and Psoriasis Area and Severity Index (PASI) for atopic eczema and psoriasis…
- Trial name
- NCT04809571
- Testing
- Photoacoustic imaging and Confocal Raman spectroscopy measurement
- Where
- Singapore
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Institute of Bioengineering and Bioimaging (IBB)
Atopic Dermatitis, Food Allergies
Probiotic Supplementation in Breastfed Newborn Infants
The purpose of this study is to investigate the dose of a probiotic supplement (Bifidobacterium longum subsp. infantis) required to achieve predominant gut colonization in healthy newborn, breastfed infants.
- Trial name
- NCT02286999
- Testing
- B. infantis
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emanual Maverakis, MD
Atopic Dermatitis
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis
This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.
- Trial name
- JADE TEEN (NCT03796676)
- Testing
- PF-04965842, PF04965842
- Where
- 136 sites in United States, Australia and 12 more
- Volunteers
- 287 people
- Sponsor
- Pfizer
Atopic Dermatitis Eczema
Effect of Ectoin Dermatitis Cream 7% on Skin Hydration and Skin Barrier Function
The aim of this prospective, uncontrolled clinical study is to evaluate the clinical effect of Ectoin® Dermatitis Cream-EHK02 on skin hydration and transepidermal water loss (TEWL) in subjects with atopic dermatitis after single…
- Trial name
- NCT04097327
- Testing
- Ectoin Dermatitis Cream 7% (EHK02)
- Where
- Germany
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Bitop AG
Seborrheic Dermatitis, Dietary Habits
Phenotypic and Functional Profile of Peripheral Blood Lymphomonocytes in Seborrheic Dermatitis.
The protocol describes a prospective, monocentric pilot study conducted at the Istituto Dermatologico San Gallicano (IFO-ISG) aimed at investigating the phenotypic and functional profile of peripheral-blood lymphomonocytes in…
- Trial name
- PHENOTYPIC (NCT07297446)
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- San Gallicano Dermatological Institute IRCCS
Psoriasis, Atopic Dermatitis
LANDSCAPE: Demographics and Treatment Patterns of Patients With Immune-Mediated Inflammatory Skin Diseases in Italian Clinical Practice
This multicenter retrospective observational registry study will collect existing clinical data from Italian centers to describe epidemiology, treatment patterns, clinical evolution, safety, and comorbidities in patients aged 12…
- Conditions
- Psoriasis, Atopic Dermatitis, Vitiligo, Alopecia Areata
- Trial name
- LANDSCAPE (NCT07336641)
- Testing
- Conventional Systemic Therapies, Biologic Therapies
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione ISIDE
Atopic Dermatitis
Comprehensive Investigation of Heart Rate Variability as a Measure of the Autonomic Nervous System in Atopic Dermatitis
The purpose of this research is to study heart rate patterns in people with moderate to severe atopic dermatitis and how itching affects those patterns.
- Trial name
- NCT00691366
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Chronic Eczema, Psoriasis
Revitalization of Damaged Skin Due to Chronic Skin Diseases
Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture…
- Conditions
- Chronic Eczema, Psoriasis, Atopic Dermatitis
- Trial name
- NCT03485560
- Testing
- ACE CSD
- Where
- 2 sites in Serbia, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Ace Cells Lab Limited
Atopic Dermatitis Eczema, Atopic Dermatitis
Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
Atopic dermatitis (AD), commonly called eczema, is one of the most frequently occurring skin conditions. It is estimated to affect around one fifth of children in developed countries and is also becoming increasingly common in…
- Conditions
- Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
- Trial name
- NCT03823794
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 148,166 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Breast Cancer, Dermatologic Complications
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation…
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00438659
- Testing
- mometasone furoate
- Where
- 189 sites in United States
- Volunteers
- 176 people
- Sponsor
- North Central Cancer Treatment Group